ReviewFrontiers in pharmacology2018
Poly(Ethylene Glycol)-Polylactide Micelles for Cancer Therapy.
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Nanoparticles-based phototherapy systems: molecular mechanisms and clinical applications.Signal transduction and targeted therapy · 2026Review
- Article
- Catechin designates individual and co-adjuvant antiproliferative effects with docetaxel in prostate cancer cell models.Toxicology research · 2025Article
- Smart Cancer Nanomedicine for Synergetic Therapy.Current medicinal chemistry · 2025Review
- Recent Trends and Applications of Nanostructure-based Drug Delivery in Alleviating Chronic Obstructive Pulmonary Disease (COPD).Current drug delivery · 2025Review
- Exploring Micelles and Nanospheres as Delivery Systems for Phenothiazine Derivatives in Cancer Therapy.Pharmaceutics · 2024Article
- The effect of comb length on theNanoscale advances · 2024Article
- Preparation and Evaluation of Folate Modified PEG-PLLA Nanoparticles Loaded with Lycorine for Glioma Treatment.Molecules (Basel, Switzerland) · 2024Article
- Tumor Microenvironment-Responsive Drug Delivery Based on Polymeric Micelles for Precision Cancer Therapy: Strategies and Prospects.Biomedicines · 2024Review
- Advanced biopolymeric materials and nanosystems for RNA/DNA vaccines: a review.Nanomedicine (London, England) · 2024Review
- Nanotechnology in cancer therapeutics, diagnosis, and management.Biotechnologia · 2024Review
- Review
- Nanoparticle-Based Approaches for Treatment of Hematological Malignancies: a Comprehensive Review.AAPS PharmSciTech · 2023Review
- Docetaxel-Loaded Methoxy poly(ethylene glycol)-poly (L-lactic Acid) Nanoparticles for Breast Cancer: Synthesis, Characterization, Method Validation, and Cytotoxicity.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Cellular Alterations in Carbohydrate and Lipid Metabolism Due to Interactions with Nanomaterials.Journal of functional biomaterials · 2023Review
- Therapeutic applications of nanobiotechnology.Journal of nanobiotechnology · 2023Review
- A Recent Review on Cancer Nanomedicine.Cancers · 2023Review
- Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy.Frontiers in oncology · 2023Review
- Multifunctional Polymeric Micelles for Cancer Therapy.Polymers · 2022Review
- Effect of Paclitaxel Stereochemistry on X-ray-Triggered Release of Paclitaxel from CaWOMolecular pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the treatment of malignancy, many therapeutic agents, including small molecules, photosensitizers, immunomodulators, proteins and genes, and so forth, have been loaded into nanocarriers for controllable cancer therapy. Among these nanocarriers, polymeric micelles have been considered as one of the most promising nanocarriers, some of which have already been applied in different stages of clinical trials. The successful advantages of polymeric micelles from bench to bedside are due to their special core/shell structures, which can carry specific drugs in certain disease conditions. Particularly, poly(ethylene glycol)-polylactide (PEG-PLA) micelles have been considered as one of the most promising platforms for drug delivery. The PEG shell effectively prevents the adsorption of proteins and phagocytes, thereby evidently extending the blood circulation period. Meanwhile, the hydrophobic PLA core can effectively encapsulate many therapeutic agents. This review summarizes recent advances in PEG-PLA micelles for the treatment of malignancy. In addition, future perspectives for the development of PEG-PLA micelles as drug delivery systems are also presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.